Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 846.50M | 933.07M | 636.46M | 632.57M | 512.78M |
Gross Profit | 344.96M | 407.09M | 202.14M | 198.74M | 135.76M |
EBITDA | 170.68M | 234.18M | -209.54M | 41.78M | -218.17M |
Net Income | 47.38M | 84.16M | -291.57M | -85.26M | -377.53M |
Balance Sheet | |||||
Total Assets | 939.13M | 944.39M | 901.38M | 1.27B | 1.47B |
Cash, Cash Equivalents and Short-Term Investments | 354.52M | 304.31M | 226.08M | 223.84M | 299.21M |
Total Debt | 185.83M | 206.07M | 217.02M | 280.24M | 361.10M |
Total Liabilities | 430.26M | 492.63M | 540.03M | 586.66M | 659.19M |
Stockholders Equity | 553.83M | 522.28M | 438.26M | 737.46M | 838.63M |
Cash Flow | |||||
Free Cash Flow | 114.10M | 148.21M | 66.16M | 9.10M | -18.73M |
Operating Cash Flow | 135.92M | 158.92M | 76.28M | 22.25M | -4.22M |
Investing Cash Flow | -21.03M | -8.64M | -23.07M | -15.74M | 47.82M |
Financing Cash Flow | -65.18M | -73.07M | -57.26M | -79.84M | -86.47M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | HK$384.46M | 8.94 | 5.95% | 11.67% | 0.81% | 27.55% | |
66 Neutral | HK$601.91M | 36.22 | 1.07% | 8.89% | -1.20% | -87.51% | |
64 Neutral | HK$450.00M | 20.55 | 5.02% | 11.11% | -15.22% | -21.37% | |
59 Neutral | HK$390.48M | 7.53 | 8.82% | 2.76% | -10.82% | -44.11% | |
58 Neutral | HK$315.03M | 15.01 | 2.73% | 3.46% | -0.69% | ― | |
51 Neutral | $7.55B | 0.30 | -61.90% | 2.27% | 17.11% | 1.58% | |
48 Neutral | HK$718.61M | ― | -10.78% | ― | -0.95% | -128.35% |
New Century Healthcare Holding Co. Ltd. has announced the composition of its board of directors and their roles, effective June 30, 2025. The board includes executive, non-executive, and independent non-executive directors, with specific members assigned to the audit, remuneration, and nomination committees. This announcement reflects the company’s commitment to structured governance and may influence its strategic decisions and stakeholder relations.
New Century Healthcare Holding Co. Ltd. has revised the terms of reference for its Nomination Committee, effective June 30, 2025. This update may impact the company’s governance structure and align its practices with the Listing Rules, potentially affecting its market positioning and stakeholder relations.
New Century Healthcare Holding Co. Ltd. has announced a change in the composition of its Nomination Committee, effective June 30, 2025. Mr. Jiang Yanfu, an independent non-executive Director, has been re-designated as the chairman of the Nomination Committee, while Ms. Xin Hong, an executive Director, has been appointed as a new member. These changes align with upcoming amendments to the Listing Rules and Corporate Governance Code, aimed at enhancing the Board’s effectiveness and diversity, thereby improving corporate governance practices.
New Century Healthcare Holding Co. Ltd. successfully held its Annual General Meeting on May 22, 2025, where all proposed resolutions were unanimously passed by shareholders. Key resolutions included the adoption of the company’s financial statements, re-election of directors, re-appointment of PricewaterhouseCoopers as auditors, and the declaration of a final dividend, reflecting strong shareholder support and stable governance.
New Century Healthcare Holding Co. Ltd. has announced its upcoming annual general meeting scheduled for May 22, 2025, in Beijing. Key agenda items include the adoption of the 2024 financial statements, re-election of directors, re-appointment of auditors, and approval of a final dividend of HK$0.0221 per share. The meeting will also consider granting the board a mandate to issue additional shares, which could impact the company’s capital structure and shareholder value.